Discovery of Potent, Selective, Orally Bioavailable Stearoyl-CoA Desaturase 1 Inhibitors

Citations Over TimeTop 10% of 2007 papers

Abstract

Stearoyl-CoA desaturase 1 (SCD1) catalyzes the committed step in the biosynthesis of monounsaturated fatty acids from saturated, long-chain fatty acids. Studies with SCD1 knockout mice have established that these animals are lean and protected from leptin deficiency-induced and diet-induced obesity, with greater whole body insulin sensitivity than wild-type animals. In this work, we have discovered a series of potent, selective, orally bioavailable SCD1 inhibitors based on a known pyridazine carboxamide template. The representative lead inhibitor 28c also demonstrates excellent cellular activity in blocking the conversion of saturated long-chain fatty acid-CoAs (LCFA-CoAs) to monounsaturated LCFA-CoAs in HepG2 cells.

Related Papers

• → A convenient and facile synthesis of pyridine, pyridazine, pyrimido-[4,5-c]pyridazine, pyrido[3,4-c]pyridazine, 1,6-naphthyridine and phthalazine derivatives(2006)16 cited
• → The synthesis of imidazo[4,5‐c] ‐ and v‐triazolo[4,5‐c] pyridazines(1967)24 cited
• → Studies on the Syntheses of N-Heterocyclic Compounds. XII. Syntheses of Pyrido[3, 4-d]pyridazine and Pyrido[2, 3-d]pyridazine Derivatives(1972)4 cited
• → The synthesis of pyrazino[2,3‐d]pyridazine and some of its derivatives(1966)20 cited
• → The synthesis of ω‐dialkylaminoalkylaminopyrazino[2,3‐d]‐, pyrido[2,3‐d]‐, imidazo[4,5‐c]‐ and imidazo[4,5‐d]pyridazines(1968)18 cited